Austin Aerts Sells 6,069 Shares of Sera Prognostics (NASDAQ:SERA) Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CFO Austin Aerts sold 6,069 shares of the firm’s stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $1.90, for a total transaction of $11,531.10. Following the completion of the sale, the chief financial officer owned 265,471 shares in the company, valued at $504,394.90. This represents a 2.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Austin Aerts also recently made the following trade(s):

• On Wednesday, March 11th, Austin Aerts sold 1,019 shares of Sera Prognostics stock. The stock was sold at an average price of $2.04, for a total transaction of $2,078.76.
• On Monday, March 9th, Austin Aerts sold 674 shares of Sera Prognostics stock. The stock was sold at an average price of $1.96, for a total transaction of $1,321.04.

Sera Prognostics Stock Performance

Shares of SERA opened at $2.13 on Friday. Sera Prognostics, Inc. has a 52 week low of $1.37 and a 52 week high of $4.20. The stock has a market capitalization of $82.22 million, a price-to-earnings ratio of -2.77 and a beta of 1.01. The stock has a fifty day moving average of $2.74 and a 200-day moving average of $3.05.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Jefferies Financial Group upgraded Sera Prognostics to a “strong-buy” rating in a research report on Monday, December 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Sera Prognostics in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $5.00.

Sera Prognostics News Roundup

Here are the key news stories impacting Sera Prognostics this week:

• Positive Sentiment: Jefferies raised SERA to a “strong-buy” in mid‑December and the MarketBeat consensus target is about $5.00 — a bullish analyst view that can support price upside in thinly traded biotech names. MarketBeat Analyst Coverage
• Neutral Sentiment: A recent comparison piece contrasts Sera with peers (Revvity), which may increase investor attention and trading interest but contains no company-specific fundamental news. Contrasting Sera Prognostics (NASDAQ:SERA) and Revvity (NYSE:RVTY)
• Neutral Sentiment: Institutions own a meaningful portion of SERA (reported ~54.6%); continued institutional interest can provide a bid under the stock even as insiders sell. Institutional Ownership Details
• Negative Sentiment: CEO Zhenya Lindgardt sold 22,639 shares at ~$1.90 on Mar 10 and 2,973 shares at ~$2.04 on Mar 11 (total ~25,612 shares, ≈$49k), representing small but notable reductions in his holdings; concentrated CEO selling can weigh on sentiment in small‑cap biotechs. SEC Filing – Lindgardt Sales
• Negative Sentiment: CFO Austin Aerts sold a total of 7,088 shares across Mar 9–11 (6,069 at $1.90 and 1,019 at $2.04), reducing his stake ~2.2% in one filing; CFO sales can be read as liquidity‑taking and may cause short‑term pressure. InsiderTrades – Aerts Sales
• Negative Sentiment: Several other insiders (General Counsel Benjamin Jackson; John J. Boniface; Paul Kearney; Robert Gardner Harrison) sold small blocks on Mar 11 (combined ~4,656 shares, ≈$9.5k). The cluster of multiple insider sales in a short window can amplify negative investor interpretation. SEC Filings – Insider Sales

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Squarepoint Ops LLC lifted its position in shares of Sera Prognostics by 8.9% in the 3rd quarter. Squarepoint Ops LLC now owns 93,063 shares of the company’s stock worth $285,000 after purchasing an additional 7,643 shares during the period. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Sera Prognostics during the fourth quarter worth $31,000. Citadel Advisors LLC raised its stake in Sera Prognostics by 1.9% during the third quarter. Citadel Advisors LLC now owns 653,746 shares of the company’s stock worth $2,000,000 after buying an additional 12,439 shares during the last quarter. Vanguard Personalized Indexing Management LLC bought a new position in Sera Prognostics during the third quarter worth $38,000. Finally, Riverview Capital Advisers LLC acquired a new position in Sera Prognostics in the second quarter valued at $35,000. Institutional investors own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.